Beike has been publishing groundbreaking research in the adult stem cell field for over 10 years utilizing umbilical cord blood and tissue as a source.
Beike’s Two Stem Cell Types
Beike provides and researches stem cells from two sources: umbilical cord blood and umbilical cord tissue. In some cases, the research protocols for some trials may include the use of more than one type of stem cells.
Umbilical Cord Blood-Derived Stem Cells (UCBSC)
For many ailments such as spinal muscular atrophy, ataxia, and optic nerve conditions, Beike Biotechnology has treatment using umbilical cord blood (UCB) stem cells. Our UCB stem cell injections consist of three subsets of stem cells: hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. As has been shown in numerous studies, hematopoietic stem cells and endothelial progenitor stem cells are likely to form tissues in the body. Mesenchymal stem cells can assist in the growth of chondrocytes (a type of cell critical to tissue renewal, particularly cartilage), liver cells, kidney cells and neurons, and also conduct repairs in relation to vascular disorders within the brain, ocular areas, and throughout the body including the heart, kidney, and pancreas. At this stage of stem cell research, it is believed that the benefits patients report have come from the cell growth factors that are released by the stem cells after their administration.
Umbilical Cord-Derived Mesenchymal Stem Cells (UCMSC)
Based upon recent research publications and experience, Beike protocols utilize UCMSC stem cells for appropriate conditions. These injections contain a higher percentage of mesenchymal stem cells than the UCB stem cell injections and closely resemble the makeup of the injections cultured from patients’ own bone marrow. Currently, we recommend all multiple sclerosis (MS) and spinal cord injury (SCI) patients receive this type of stem cell injection as the cells not only produce important growth factors and differentiate into desired cell types but can also regulate the immune system, reducing inflammation, scarring, and cell apoptosis.
Below you can see Beike’s published research papers as well as clinical translation case studies for stem cell treatments of many different conditions. The papers are listed alphabetically.
MAR (MHC Antigen Receptor) is a class of fully human single domain antibodies that bind MHC antigen complex and is a “TCR-like antibody”. Binding to MHC antigen complexes enables MAR to target intracellular targets, opening up new possibilities to cancer immunotherapies.
For more information on MAR please visit http://timmune.com, our subsidiary for these technologies.
TriTE (Tri-functional T cell Engager) is a fusion protein platform with a unique combination of antigen binding domains, a Sushi domain IL15 binding pair and PD1. It provides an improved micro-environment for cancer immunotherapy.
For more information on TriTE please visit http://timmune.com, our subsidiary for these technologies.
MAR-T is a variant of CAR-T for adoptive T cell cancer therapy. It utilizes part of our proprietary TriTE platform and MAR and results in a T cell with improved micro-environment and more binding targets with better binding specificity and affinity. This increases its potential for cancer immunotherapies over the traditional CAR-T.
For more information on MAR-T please visit http://timmune.com, our subsidiary for these technologies.
National network for comprehensive cell banking and regional cell preparation center – Asia’s largest cell banking and preparation service network
- Beike has constructed a “cell therapy expressway network” which ensures quality and timeliness of meeting clinical therapy needs.
- This network offers an innovative public technological platform and infrastructure for clinical translation of cell therapy technologies. The network is already established in Shenzhen, Jiangsu, Guizhou, Jiangxi, Guangxi and Xinjiang, and is still expanding
- The (name of machine or the technology) is a joint project between Beike and MediBIC. It is an automated sterile robotics system capable of culturing cells en masse at standardized levels consistently.
- (Machine/Technology name) allows for decentralized cell preparation, enabling cultures to be fully prepared in close proximity to sites for usage and eliminates the need for on-site specialized personnel to prepare cells as well as human error.
For more information on the compact automatic cell culture system, please visit (site not yet registered).